Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP01 - Early Stage/Localized Disease
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Early Stage/Localized Disease
-
+
FP01.05 - The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC
00:00 - 00:00 | Presenter: Andrew Piper-Vallillo
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.23 - Veliparib (V) in Combination with Carboplatin/Paclitaxel (C/P)-Based Chemoradiotherapy (CRT) in Patients With Stage III NSCLC
00:00 - 00:00 | Presenter: David Kozono
- Abstract
Loading...
-
+
P48 - Small Cell Lung Cancer/NET - Chemo - IO
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/NET
-
+
P48.02 - NRG Oncology/Alliance LU005: Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Kristin A. Higgins
- Abstract
Loading...
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.01 - TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezolizumab with Chemoradiation (AFT-16)
00:00 - 00:00 | Presenter: Woo Yul Byun
- Abstract
Loading... -
+
P79.06 - CHIO3: ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer (AFT-46)
00:00 - 00:00 | Presenter: Linda W Martin
- Abstract
Loading...
-
+
OA01 - Established Drugs in Special Populations and New Drugs in Established Populations
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
OA01.04 - Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
09:25 - 09:35 | Presenter: Fred R Hirsch
- Abstract
Loading...
-
+
MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
MA08.10 - LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis
17:20 - 17:25 | Presenter: Philip Christopher Mack
- Abstract
Loading...
-
+
MA11 - Expanding Targetable Genetic Alterations in NSCLC
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Targeted Therapy - Clinically Focused
-
+
MA11.10 - Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)
14:50 - 14:55 | Presenter: David Kozono
- Abstract
Loading...
